Prime Medicine expects first approval next year for chronic granulomous disease; Wilson disease Phase 1-2 began dosing in October and targets 2027 data, while alpha-1 antitrypsin’s first patient dose is expected end of the year or soon after.
PRME · Prime Medicine, Inc. · Documents
Substantial doubt about the company's ability to continue as a going concern.
“As a result, we concluded that substantial doubt exists about our ability to continue as a going concern for 12 months from the date these condensed consolidated financial statements are issued.”View the 10-Q filed Nov 12, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Prime Medicine, Inc. concluded substantial doubt exists about its ability to continue as a going concern for 12 months, reporting $61.2 million in cash, cash equivalents and short-term investments as of September 30, 2026, and $74.8 million including restricted cash.
Prime Medicine raised $143.7 million in gross proceeds, reporting pro-forma cash of approximately $209.5 million and a runway through 2027 after dosing the first patient with PM577a and receiving FDA clearance for PM647.
Prime Medicine priced 35,714,286 shares at $3.50 per share and granted underwriters an option for 5,357,142 additional shares. Estimated net proceeds, including full option exercise and after underwriting discounts, commissions and offering expenses, are approximately $134.7 million.
Prime Medicine estimated cash, cash equivalents and short-term investments of approximately $61.2 million as of September 30, 2026, excluding approximately $13.7 million of restricted cash; the unaudited figures remained subject to quarter-end closing adjustments.